Follistatin

Follistatin is presented as a protein that interacts with myostatin/GDF-8 and related activin-family signals. The source describes this binding as preventing those ligands from engaging activin type II receptors, which may reduce signaling pathways that normally limit skeletal-muscle growth. Because it can affect more than one TGF-beta family ligand, its biological effects may be broader than a myostatin-only blocker.

The source highlights early human work with AAV1.CMV.FS344 gene transfer delivered into quadriceps muscle in six men with Becker muscular dystrophy. It reports functional improvement on the 6-minute walk test in several participants, mixed individual responses, biopsy findings consistent with less fibrosis and larger or more normalized fibers, and no serious adverse effects in that small study. The same general gene-transfer strategy is also described as having been studied in sporadic inclusion body myositis. Important limitations remain: the cited human evidence is small, open label, locally delivered, and not yet supported by large placebo-controlled trials. The source distinguishes this research from non-study use of injectable follistatin peptide for physique goals, where controlled human evidence is described as essentially absent.